Recent Articles in CRO/CMO Services

ClinChoice, a US-China-EU clinical CMO, closed a $150 million Series E round financing from China investors. Formerly known as Fountain Medical Development, the company began life in Tianjin, China and added facilities in the US. ClinChoice CEO Ling Zhen told Endpoint News the company will use the new capital to expand in Europe and Southeast Asia, possibly via M&A, while adding remote monitoring and data analytic services. The round was led by Legend Capital and co-invested by Taikang Life Insurance, Sherpa Healthcare Partners and existing shareholders Lilly Asia Ventures and Apricot Capital. More details....

Share this with colleagues:  

Shanghai ZhenGe Biotech completed a $100 million C Round to strengthen its biologic drug CDMO services. The company offers end-to-end services from concept to commercialization to help customers discover, develop and manufacture biologics. Founded in 2017, ZhenGe has worked with more than 100 biopharma and biotech customers, completing over 150 projects that range from cell line development projects to IND applications and clinical trial production. ZhenGe has expertise with monoclonal and bispecific antibodies, ADCs, fusion proteins and vaccines. The C Round was led by Goldman Sachs Asset Management and Sofina. More details....

Share this with colleagues:

Frontage Shanghai, a division of US-China CRO Frontage Holdings, acquired a 70% stake in Wuhan Heyan Biomedical Technology, a discovery CRO. Heyan offers target-based in vitro pharmacodynamic screening and early pharmacological pharmacodynamic evaluation services for biologic drug discovery. Its technical services include screening of drug targets, customized biological assay development and detection services. Frontage, which is majority owned by Hangzhou's TigerMed, offers drug evaluation, product development/CMC and clinical services. More details....

Share this with colleagues:

dMed-Clinipace, a China-US full-service clinical CRO, completed a $50 million Series C+ financing. In April of this year, dMed and Clinipace announced their merger, which created a global company offering CRO services for oncology and rare diseases, with expertise in clinical development, regulatory, pharmacovigilance and clinical analytics. The C+ round, which will help finance the merger, was led by Springhill Fund, with contributions from Rock Springs Capital and Superstring Capital. d-Med is headquartered in Shanghai and Clinipace in North Carolina. More details....

Share this with colleagues: